TP53 and breast cancer

TP53 and ovarian cancer

✍ Monique Schuijer; Els M.J.J. Berns 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB

Ovarian cancer represents the fourth most frequent type of cancer among females and is the leading cause of death from gynecological cancer in the western world. This review describes gene alterations in ovarian cancer. Specific emphasis is placed on genetic alterations and the prevalence of TP53 (p

TP53 mutations in familial breast cancer

TP53 mutations in familial breast cancer: Functional aspects

✍ Milena Gasco; Isik G Yulug; Tim Crook 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

Mutation in p53 (TP53) remains one of the most commonly described genetic events in human neoplasia. The occurrence of mutations is somewhat less common in sporadic breast carcinomas than in other cancers, with an overall frequency of about 20%. There is, however, evidence that p53 is mutated at a s

TP53 family members and human cancers

✍ Jean Bénard; Setha Douc-Rasy; Jean-Charles Ahomadegbe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB

Based on gene sequence homologies, a p53 (TP53) gene family become apparent with the addition of the most recently identified p63 (TP73L; formerly TP63) and p73 (TP73) genes to the already known p53. The p53 gene encodes for a unique protein eliciting well-known tumor suppressor gene (TSG) propertie

TP53 mutation in colorectal cancer

✍ Barry Iacopetta 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

Approximately half of all colorectal cancers show p53 (TP53) gene mutations, with higher frequencies observed in distal colon and rectal tumors and lower frequencies in proximal tumors and those with the microsatellite instability or methylator phenotypes. Alterations to this gene appear to have lit

TP53 and MYC gene alterations independen

TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients

✍ Els M.J. J. Berns; Jan G. M. Klijn; Marcel Smid; Iris L. van Staveren; Maxime P. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 792 KB

We intended to establish the frequency of exon-specific TP53 gene alterations and the relation t o patient and tumor characteristics and clinical outcome of patients with breast cancer. By using polymerase chain reaction-single-strand conformation polymorphism analysis (KR-SSCP) and sequencing techn

TP53 mutations in human skin cancers

✍ Giuseppina Giglia-Mari; Alain Sarasin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB

The p53 gene (TP53) is mutated in numerous human cancers. We have used it as a molecular target to characterize the induction of mutations in human skin cancers. About 50% of all skin cancers in normal individuals exhibit p53 mutations. This frequency rises to 90% in skin cancers of patients with th